Xoma reported $5.12M in Selling and Administration Expenses for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Abbvie ABBV:US $ 3.06B 110M
Agenus AGEN:US $ 18.95M 3.02M
Agios Pharmaceuticals AGIO:US $ 31.51M 13K
Ardelyx ARDX:US $ 19.34M 5.1M
Biomarin Pharmaceutical BMRN:US $ 194.62M 22.94M
Celldex Therapeutics CLDX:US $ 6.91M 670K
Chimerix CMRX:US 5.63M 391K
Curis CRIS:US $ 5.67M 900K
Eli Lilly And LLY:US $ 1.56B 34.1M
Emergent Biosolutions EBS:US $ 84.8M 9.4M
Epizyme EPZM:US $ 27.2M 3.66M
Intercept Pharmaceuticals ICPT:US $ 50.01M 10.58M
Life Technologies LIFE:US $ 3.48M 797K
Macrogenics MGNX:US $ 16.25M 670K
Novartis NOVN:VX 3.5B 486M
Novartis NVS:US 3.5B 486M
Prothena PRTA:US 11.84M 371K
Regeneron Pharmaceuticals REGN:US $ 450M 109.6M
Teva Pharmaceutical Industries TEVA:US 819M 39M
Xoma XOMA:US $ 5.12M 422K
YTE INCY:US $ 209.58M 16.62M